Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
MDS/MPN Diseases

- Chronic Myelomonocytic Leukemia
- Atypical Chronic Myeloid Leukemia, bcr/abl1 neg
- Juvenile Myelomonocytic Leukemia
- MDS / MPN, Unclassified
MDS/MPN: WHO Classification

Monoclonal hematopoietic neoplasms with clinical, laboratory or morphologic findings of both myelodysplastic syndromes and chronic myeloproliferative diseases
MDS/MPD: General features

- Hypercellular bone marrow
  - Proliferation of one or more myeloid lineages
    - May be effective and functional with increased circulating cells
    - Or morphologically and functionally dysplastic

- Cytopenias
  - Ineffective proliferation of other lineages

- Blasts < 20%

- Splenomegaly and hepatomegaly
MDS/MPD: Exclusion criteria

- Patients with well-defined myeloproliferative diseases who develop dysplasia and ineffective hematopoiesis
- Ph or Bcr/Abl
Chronic Myelomonocytic Leukemia (CMML)
CMML: Definition

Monoclonal hematopoietic disorder of bone marrow stem cells in which monocytosis is a major defining feature.
CMML: Etiology/Epidemiology

- Unknown
- Occupational or environmental carcinogens, ionizing irradiation and cytotoxic agents
- 3/100,000 over the age of 60, annually
- Median age at diagnosis: 65-75 years
- Male predominance, M:F= 1.5-3:1
CMML: Diagnostic criteria

- Persistent monocytosis (>1 x 10^9/L, or > 1 x 10^3/uL) in PB, Monocytes >10% of WBCs
- No Ph or Bcr/Abl
- <20% blasts in PB or BM, 20% may include:
  - Myeloblasts
  - Monoblasts
  - Promonocytes
- May have dysplasia in one or more myeloid lineages (not necessary)
CMML: Diagnostic criteria

If dysplasia is minimal or absent, CMML can be diagnosed if:

- Monoclonal cytogenetic abnormality in marrow cells, or
- Monocytosis persistent for at least 3 mo, and
- All other causes of monocytosis are excluded
CMML: Diagnostic criteria

- Dysgranulopoiesis present in most cases, and may be more prominent in cases with normal or low WBC count
  - Neutrophils with nuclear hypolobation
  - Neutrophils with abnormal cytoplasmic granulation
- Mild anemia
- Moderate thrombocytopenia with atypical platelets
CMML: Clinical features

- Symptoms: fatigue, weight loss, fever, night sweats, infection, bleeding

- Sites of involvement
  - PB and BM always involved
  - Most common sites of extramedullary leukemic infiltration
    - Spleen
    - Liver
    - Skin
    - LNs
Monoblasts
Promonocytes
CMML: PB morphology

Monocytosis, dysplastic PMNs
CMML: BM Morphology

- Hypercellular in >75% of cases
- Granulocytic proliferation
- Monocytic proliferation: positive for these non-specific esterases (NSE)
  - Alpha naphthyl acetate esterase
  - Alpha naphthyl butyrate esterase
Butyrate
CMML: BM Morphology

- Dysgranulopoiesis in most cases
- Dyserythropoiesis (> 50%)
  - Megaloblastic changes, abnormal nuclear contours, ringed-sideroblasts
- Megakaryocytic dysplasia (80%)
  - Abnormal nuclear lobation and micromegs
- Variable degree of fibrosis (30%)
CMML: BM Morphology
CMML: Clinical features

In about 50%
- WBC count normal or slightly decreased
- “MDS-like” picture

In about 50%
- WBC count increased
- “MPD-like” picture
CMML: Clinical features

“MDS-CMML” and “MPD-CMML”

- Arbitrary cut-off for leukocyte count (13,000/µl)
  - Little evidence of clinical relevance
  - Duration of survival times similar
  - No cytogenetic or molecular differences
  - MDS-type may become more proliferative
CMML: Morphology; other organ systems

- **Spleen**
  - Red pulp infiltration by leukemic cells

- **Lymph node involvement**
  - Uncommon
  - Sign of transformation to a more acute phase
  - LN may be diffusely infiltrated by myeloid blasts
CMML: Classification

- **CMML-1**
  - PB blasts <5% of WBC and <10% of nucleated BM cells

- **CMML-2**
  - PB blasts 5-19% or BM blasts 10-19% or with Auer rods
  - May be at risk of rapid transformation to acute leukemia and poor prognosis

- **AML**
  - PB and/or BM blasts 20% or more
Degree of leukocytosis, neutrophilia and dysplasia is variable.

- 50% of cases:↑ WBC with minimal dysgranulopoiesis
- 50% of cases: Normal WBC with absolute monocytosis, neutropenia and dysgranulopoiesis.
CMML-2

- Blasts 5-19% in the blood
- Blasts <20% in BM
- Auer rods present
CMML: Immunophenotype

- CD33/13 (+), variable CD14/64/68
- Increased percentage of CD34(+) cells may be associated with early transformation to acute leukemia
CMML: Genetics

- Nonspecific cytogenetic abnormalities in 20-40%
  - Trisomy 8
  - del (7q)
  - Structural abnormalities of 12p
  - JAK2 V617F uncommon
  - Abnormalities of 11q23 uncommon -> suggest acute leukemia
CMML: Genetics

- RAS point mutations (40%)
- i(17q)
  - More aggressive course
Cases that may resemble CMML with marked eosinophilia:
- t(5;12)(q31;p12) resulting in ETV6/PDGFRB abnormal fusion gene -> MPN with eosinophilia and ETV6/PDGFRB mutation
- del(4)(q12) resulting in FIP1L1/PDGFRB abnormal fusion gene -> MPN with eosinophilia and FIP1L1/PDGFRB mutation
CMML: prognosis/predictive factors

Prognosis
- Median survival 20-40 months
- 15-30% progress to acute leukemia

Predictive factors
- PB and BM blast percentage (most important factor)
- Splenomegaly
- Severity of anemia
- Degree of leukocytosis
Atypical Chronic Myeloid Leukemia (aCML), bcr/abl1 negative
aCML: Characteristic features

- Leukocytosis with dysplastic immature and mature neutrophils
- Multilineage dysplasia
- No Ph or Bcr/Abl
aCML: Epidemiology

- Unknown incidence
- Estimated 1-2 cases for every 100 Ph(+) CML
- Median age: 7th-8th decades
- M:F = 1-2.5:1
aCML: Diagnostic criteria

- PB leukocytosis (mature and immature neutrophils), WBC >13 \( \times 10^9/L \) (13 \( \times 10^3/uL \))
- Prominent dysgranulopoiesis (major characteristics)
- No Ph or Bcr/Abl
- No rearrangement of PDGFRA or PDGFRB
- Neutrophil precursors (promyelocytes, myelocytes, metamyelocytes) >10% of WBCs
- Basophils <2% of WBCs
aCML: Diagnostic criteria

- Monocytes < 10% of WBC
- Hypercellular BM with granulocytic proliferation and dysplasia, with or without erythroid and megakaryocytic dysplasia
- Some cases may have megakaryocytes similar to those in CML
- <20% blasts in PB and BM
aCML: Clinical features

- PB and BM always involved
- Spleen and liver involvement: common
- Most patients have symptoms related to
  - Anemia
  - Thrombocytopenia
  - Splenomegaly
aCML: PB morphology
aCML, BM

- Hypercellularity due granulocytic proliferation. Bone marrow biopsy.
aCML: BM morphology

- BM megakaryopoiesis and erythropoiesis are variable in quantity
- M:E >10:1
- Increased reticulin fibers at diagnosis or later in course of disease
aCML: Cytochemistry/Immunophenotype

- No specific abnormalities
aCML: Genetics

- +8, +13, del(20q), i(17q), del(12p)
  - 80% of cases
  - Not specific
  - No Ph or Bcr/Abl1
  - Some cases with JAK2 V617F
  - 30% of cases with NRAS or KRAS
aCML: Course and prognosis

- Median survival < 20 months
- Poor prognostic factors
  - Thrombocytopenia
  - Marked anemia
- 25-40% evolve to acute leukemia
- The remaining patients die of marrow failure
aCML: Variant

Syndrome of abnormal chromatin clumping

- PB morphology
  - high percentage of immature and mature neutrophils with exaggerated clumping of chromatin (“chromatin condensation”)
  - nuclear hypolobation and cytoplasmic hypogranularity are common
  - WBC count usually increased
  - Severe anemia and thrombocytopenia
aCML

- Syndrome of abnormal chromatin clumping
  - BM morphology
    - hypercellular
    - granulocytic proliferation with nuclear abnormalities similar to PB
    - Moderate dysplasia in erythroblastic and megakaryocytic lineages
  - Survival is similar to aCML
aCML: Peripheral Blood Smear

Abnormal chromatin clumping
aCML: Aspirate Smear
aCML: Aspirate Smear